A Phase 1 interventional study of Oraxol in Breastcancer, sponsored by Health Hope Pharma. Completed at 6 sites in Taiwan. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-03-12.
Sponsored by Health Hope Pharma · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 380 studies in Breast Neoplasms with a site in Taiwan — 68 open to participants now, 133 under way, 60 of them phase 3. Breast Neoplasms · Taiwan.
Among the 380 studies in Breast Neoplasms with a site in Taiwan, this one is the 306th largest by enrollment of the 332 interventional ones that give a count, is one of 18 that started in 2017, is one of 25 in phase 1, and was the 156th registered.
14,855 studies on the registry are indexed under Breast Neoplasms; 3,321 are open to participants now.
Browse Breast Neoplasms studies →68 of the 380 studies in Breast Neoplasms with a site in Taiwan are open now. Recruiting first, the newest first:
Chung Yuan Christian University · Sites in Taiwan
Ages 20+
Daiichi Sankyo · Sites in Taiwan, United States, Belgium and 5 more countries
Ages 18+
CHING-RONG HUANG · Sites in Taiwan
Ages 18–75 · Women only
BeOne Medicines · Sites in Taiwan, United States, Australia and 13 more countries
Ages 18+
Hoffmann-La Roche · Sites in Taiwan, United States, Argentina and 23 more countries
Ages 18+
A study can be open while its sites in Taiwan have not opened yet or have stopped. Only those recruiting at a site in Taiwan →
Of the 2,403 Breast Neoplasms studies recruiting now, 1,574 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.
This study: 18 Years and older · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
380 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 46 · Phase 2 98 · Phase 3 136 · Phase 4 5
First in 1996; this study’s year is marked. 18 started in 2017.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 28 is below the median of 72 across 10,921 interventional studies indexed under Breast Neoplasms.
Median enrollment 222 across the 332 interventional studies, 205 across the 46 observational. Of the 185 that completed or were terminated, 103 (56%) have results posted.
This tab as a report to print or save as PDF → With an account.
237 of 380 have an industry lead sponsor. The 10 most frequent:
Health Hope Pharma is the lead sponsor of 4 studies on the registry; 2 are open to participants now.
Health Hope Pharma has 3 studies filed under Breast Neoplasms — fewer than ten, so there is no comparison to draw.
34 of the studies in Breast Neoplasms with a site in Taiwan that are under way reach primary completion within a year, 13 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04639986Phase 3Gilead SciencesAsian Study of Sacituzumab Govitecan (IMMU-132) in HR+/HER2- Metastatic Breast Cancer (MBC) | 2026-12 |
| NCT04873362Phase 3Hoffmann-La RocheA Study Evaluating the Efficacy and Safety of Adjuvant Atezolizumab or Placebo and Trastuzumab Emtansine for Participants With HER2-Positive Breast Cancer at High Risk of Recurrence Following Preoperative Therapy | 2027-03-31 |
| NCT05696626Phase 3LeonaBioEvaluation of Lasofoxifene Combined With Abemaciclib Compared With Fulvestrant Combined With Abemaciclib in Locally Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation | 2027-04 |
| NCT04421963Phase 3AstraZenecaRoll Over StudY for Patients Who Have Completed a Previous Oncology Study With Olaparib | 2027-04-06 |
| NCT05774951Phase 3AstraZenecaA Study of Camizestrant in ER+/HER2- Early Breast Cancer After at Least 2 Years of Standard Adjuvant Endocrine Therapy | 2027-04-20 |
Add all 34 to your calendar (.ics) → With an account.
Among the 380 studies in Breast Neoplasms with a site in Taiwan, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is a multicenter, open-label, single-arm PK study in patients for whom paclitaxel treatment is indicated.
This is a multicenter, open-label, single-arm PK study in approximately 24 breast cancer patients for whom paclitaxel treatment is indicated. The study contains 3 periods: the Screening / Baseline Period, the Treatment Period, and the Follow-up Period. A Final Visit will occur within 7 days of the last dose of study treatment. If subjects achieve stable disease (SD), partial response (PR), or complete response (CR) at the end of the Treatment Period, they may continue Oraxol treatment in a separate extension study.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Adequate hematological status as demonstrated by not requiring transfusion support or granulocyte-colony stimulating factor (G-CSF) maintain:
Adequate liver function
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.
Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
RECIST
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Absolute neutrophil count (ANC)
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Adjuvant and neoadjuvant
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Brain metastases
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Leptomeningeal disease
Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.
Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Subjects will receive Oraxol 205 mg/m2 daily x 3 days weekly for up to 16 weeks.
Drug: Oraxol
HM30181 methanesulfonate monohydrate - supplied as 15-mg HM30181AK-US tablets, Paclitaxel - supplied as 30-mg capsules
Also known as: HM30181 methanesulfonate monohydrate, Oral paclitaxel capsules
PK Parameters for paclitaxel_AUC (0-52)
PK parameters were summarized using the mean, SD
Time frame: PK sampling timepoints: predose, and at 1, 2, 3, and 4 hours after dosing of Day 1, 2, 3 at Week 1 and 4
PK Parameters for paclitaxel_Cmax
PK parameters were summarized using the mean, SD
Time frame: PK sampling timepoints: predose, and at 1, 2, 3, and 4 hours after dosing of Day 1, 2, 3 at Week 1 and 4
PK Parameters for paclitaxel_Ctrough(24)
PK parameters were summarized using the mean, SD
Time frame: PK sampling timepoints: predose, and at 1, 2, 3, and 4 hours after dosing of Day 1, 2, 3 at Week 1 and 4
PK Parameters for paclitaxel_Ctrough(48)
PK parameters were summarized using the mean, SD
Time frame: PK sampling timepoints: predose, and at 1, 2, 3, and 4 hours after dosing of Day 1, 2, 3 at Week 1 and 4
PK Parameters for paclitaxel_Cmax(0-24)
PK parameters were summarized using the mean, SD
Time frame: PK sampling timepoints: predose, and at 1, 2, 3, and 4 hours after dosing of Day 1, 2, 3 at Week 1 and 4
PK Parameters for paclitaxel_Cmax(24-48)
PK parameters were summarized using the mean, SD
Time frame: PK sampling timepoints: predose, and at 1, 2, 3, and 4 hours after dosing of Day 1, 2, 3 at Week 1 and 4
PK Parameters for paclitaxel_Cmax(48-52)
PK parameters were summarized using the mean, SD
Time frame: PK sampling timepoints: predose, and at 1, 2, 3, and 4 hours after dosing of Day 1, 2, 3 at Week 1 and 4
PK Parameters for paclitaxel_tmax(0-24)
PK parameters were summarized using the median, minimum, maximum
Time frame: PK sampling timepoints: predose, and at 1, 2, 3, and 4 hours after dosing of Day 1, 2, 3 at Week 1 and 4
PK Parameters for paclitaxel_tmax(24-48)
PK parameters were summarized using the median, minimum, maximum
Time frame: PK sampling timepoints: predose, and at 1, 2, 3, and 4 hours after dosing of Day 1, 2, 3 at Week 1 and 4
PK Parameters for paclitaxel_tmax(48-52)
PK parameters were summarized using the median, minimum, maximum
Time frame: PK sampling timepoints: predose, and at 1, 2, 3, and 4 hours after dosing of Day 1, 2, 3 at Week 1 and 4
Safety of Oraxol in Breast Cancer Patients
Safety was assessed by evaluating treatment-emergent adverse events (TEAEs) including SAEs, laboratory evaluations (hematology, blood chemistry, and urinalysis), vital signs, physical examinations, and electrocardiograms (ECGs).
Time frame: From enrollment through study completion, approximately 17 weeks
Response Rate
Tumor response rate and 95% confidence interval (CI) were evaluated based on the number of subjects with any post-baseline CR or PR per RECIST 1.1 as assessed by the Investigator and the ICRRC.
Time frame: From baseline through study completion, around 21 weeks
Progression-free Survival
PFS was analyzed based on the Response Evaluable Population. The Kaplan-Meier (KM) method was used to estimate the medians of these variables with 95% CIs. The Response Evaluable Population included all subjects who received at least 1 dose of study treatment and had at least 1 posttreatment tumor response evaluation
Time frame: From baseline through study completion, around 21 weeks
Overall Survival
OS was analyzed based on the Response Evaluable Population. The Kaplan-Meier (KM) method was used to estimate the medians of these variables with 95% CIs. The Response Evaluable Population included all subjects who received at least 1 dose of study treatment and had at least 1 posttreatment tumor response evaluation
Time frame: From baseline through study completion, around 21 weeks
| Milestone | Oraxol (Oral Paclitaxel Plus HM30181) |
|---|---|
| Started | 31 |
| Completed | 28 |
| Not completed | 3 |
| Milestone | Oraxol (Oral Paclitaxel Plus HM30181) |
|---|---|
| Started | 28 |
| Completed | 20 |
| Not completed | 8 |
| Withdrew: Withdrawal by subject | 3 |
| Withdrew: Death | 1 |
| Withdrew: Adverse event | 1 |
| Withdrew: Progressive disease | 3 |
PK parameters were summarized using the mean, SD
| ng*hr/mL | Oraxol (Oral Paclitaxel Plus HM30181) |
|---|---|
| Week 1 | 3419 ± 1475 |
| Week 4 | 3224 ± 1150 |
PK parameters were summarized using the mean, SD
| ng/mL | Oraxol (Oral Paclitaxel Plus HM30181) |
|---|---|
| Week 1 | 366 ± 143 |
| Week 4 | 356 ± 140 |
PK parameters were summarized using the mean, SD
| ng/mL | Oraxol (Oral Paclitaxel Plus HM30181) |
|---|---|
| Week 1 | 11.0 ± 4.0 |
| Week 4 | 12.5 ± 8.7 |
PK parameters were summarized using the mean, SD
| ng/mL | Oraxol (Oral Paclitaxel Plus HM30181) |
|---|---|
| Week 1 | 12.6 ± 4.3 |
| Week 4 | 11.7 ± 3.3 |
PK parameters were summarized using the mean, SD
| ng/mL | Oraxol (Oral Paclitaxel Plus HM30181) |
|---|---|
| Week 1 | 312 ± 132 |
| Week 4 | 267 ± 135 |
PK parameters were summarized using the mean, SD
| ng/mL | Oraxol (Oral Paclitaxel Plus HM30181) |
|---|---|
| Week 1 | 274 ± 144 |
| Week 4 | 298 ± 127 |
PK parameters were summarized using the mean, SD
| ng/mL | Oraxol (Oral Paclitaxel Plus HM30181) |
|---|---|
| Week 1 | 287 ± 144 |
| Week 4 | 288 ± 144 |
PK parameters were summarized using the median, minimum, maximum
| hour | Oraxol (Oral Paclitaxel Plus HM30181) |
|---|---|
| Week 1 | 1.05 (0.97 to 2.12) |
| Week 4 | 1.07 (0.93 to 2.12) |
PK parameters were summarized using the median, minimum, maximum
| hour | Oraxol (Oral Paclitaxel Plus HM30181) |
|---|---|
| Week 1 | 25.03 (24.47 to 27.03) |
| Week 4 | 25.00 (22.78 to 27.33) |
PK parameters were summarized using the median, minimum, maximum
| hour | Oraxol (Oral Paclitaxel Plus HM30181) |
|---|---|
| Week 1 | 49.02 (48.22 to 51.03) |
| Week 4 | 49.03 (47.05 to 51.05) |
Safety was assessed by evaluating treatment-emergent adverse events (TEAEs) including SAEs, laboratory evaluations (hematology, blood chemistry, and urinalysis), vital signs, physical examinations, and electrocardiograms (ECGs).
| Participants | Oraxol (Oral Paclitaxel Plus HM30181) |
|---|---|
| Subjects with At Least One TEAE | 27 |
| TEAE leading to dose interruption or reduction | 19 |
| TEAE leading to study drug discontinuation | 2 |
| TEAE leading to discontinuation from the study | 2 |
| Serious TEAE | 8 |
| TEAE related to Oraxol | 27 |
| TEAE related to progression of disease | 4 |
| Death | 1 |
| TEAE with action taken for other treatments | 24 |
| Subjects with At Least One Grade ≥3 TEAE | 19 |
Tumor response rate and 95% confidence interval (CI) were evaluated based on the number of subjects with any post-baseline CR or PR per RECIST 1.1 as assessed by the Investigator and the ICRRC.
| Participants | Oraxol (Oral Paclitaxel Plus HM30181) |
|---|---|
| Investigator Assessment — Complete response (CR) | 0 |
| Investigator Assessment — Partial response (PR) | 11 |
| Investigator Assessment — Stable disease (SD) | 13 |
| Investigator Assessment — Progressive disease (PD) | 1 |
| Investigator Assessment — Non-evaluable (NE) | 1 |
| ICRRC Assessment — Complete response (CR) | 0 |
| ICRRC Assessment — Partial response (PR) | 10 |
| ICRRC Assessment — Stable disease (SD) | 12 |
| ICRRC Assessment — Progressive disease (PD) | 3 |
| ICRRC Assessment — Non-evaluable (NE) | 0 |
PFS was analyzed based on the Response Evaluable Population. The Kaplan-Meier (KM) method was used to estimate the medians of these variables with 95% CIs. The Response Evaluable Population included all subjects who received at least 1 dose of study treatment and had at least 1 posttreatment tumor response evaluation
| weeks | Oraxol (Oral Paclitaxel Plus HM30181) |
|---|---|
| Investigator Assessment | NA (NA to NA) |
| ICRRC Assessment | 15.86 (15.00 to NA) |
OS was analyzed based on the Response Evaluable Population. The Kaplan-Meier (KM) method was used to estimate the medians of these variables with 95% CIs. The Response Evaluable Population included all subjects who received at least 1 dose of study treatment and had at least 1 posttreatment tumor response evaluation
| weeks | Oraxol (Oral Paclitaxel Plus HM30181) |
|---|---|
| Overall Survival | NA (NA to NA) |
Collected over An AE was any untoward medical occurrence in a subject or clinical investigation subject, and included events occurring from the time a subject signed the ICF through the last subject contact. The period is up to 21 weeks.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Oraxol (Oral Paclitaxel Plus HM30181) | 1/28 (3.6%) | 8/28 (28.6%) | 27/28 (96.4%) |
| Event | Oraxol (Oral Paclitaxel Plus HM30181) |
|---|---|
| NeutropeniaBlood and lymphatic system disorders | 3/28 |
| Hepatitis acuteHepatobiliary disorders | 1/28 |
| PneumoniaInfections and infestations | 1/28 |
| Septic shockInfections and infestations | 1/28 |
| Femur fractureInjury, poisoning and procedural complications | 1/28 |
| Infected neoplasmNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 1/28 |
| Deep vein thrombosisVascular disorders | 1/28 |
| Event | Oraxol (Oral Paclitaxel Plus HM30181) |
|---|---|
| DiarrhoeaGastrointestinal disorders | 16/28 |
| NeutropeniaBlood and lymphatic system disorders | 16/28 |
| AlopeciaSkin and subcutaneous tissue disorders | 12/28 |
| NauseaGastrointestinal disorders | 9/28 |
| AnaemiaBlood and lymphatic system disorders | 6/28 |
| Alanine aminotransferase increasedInvestigations | 5/28 |
| Aspartate aminotransferase increasedInvestigations | 5/28 |
| VomitingGastrointestinal disorders | 4/28 |
| Neuropathy peripheralNervous system disorders | 4/28 |
| Decreased appetiteMetabolism and nutrition disorders | 4/28 |
A total of 31 subjects were screened; 3 subjects were screen failures and were not included in the analysis
| Age, Continuous(years) | Oraxol (Oral Paclitaxel Plus HM30181) |
|---|---|
| Mean | 56.6 ± 9.04 |
| Sex: Female, Male(Participants) | Oraxol (Oral Paclitaxel Plus HM30181) |
|---|---|
| Female | 28 |
| Male | 0 |
| Race (NIH/OMB)(Participants) | Oraxol (Oral Paclitaxel Plus HM30181) |
|---|---|
| American Indian or Alaska Native | 0 |
| Asian | 28 |
| Native Hawaiian or Other Pacific Islander | 0 |
| Black or African American | 0 |
| White | 0 |
| More than one race | 0 |
| Unknown or Not Reported | 0 |
| Region of Enrollment(participants) | Oraxol (Oral Paclitaxel Plus HM30181) |
|---|---|
| Taiwan | 28 |
| ECOG(Participants) | Oraxol (Oral Paclitaxel Plus HM30181) |
|---|---|
| 0 | 24 |
| 1 | 4 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from May 2017 to primary completion in Nov 2018, 18 months.
Results were first posted in Jul 2020, 1 year 7 months after primary completion.
Of 390 industry-sponsored phase 1 interventional studies under Breast Neoplasms, half reached primary completion within 39 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 56. This study's 18 months is below that.
Counting every sponsor, half of 763 studies reached it within 44 months; a quarter within 25 and three quarters within 65.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Oraxol
Health Hope Pharma